Modulation of G6PD was proven to affect bladder cancer via ROS accumulation and the AKT pathway in vitro (43), and knockdown of G6PD reduces ROS accumulation and enhances apoptosis of bladder cancer cells. Here, G6PD is linked to urinary bladder carcinoma.